Q4 Comp plan

Discussion in 'OPKO Renal' started by anonymous, Sep 15, 2017 at 9:53 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Upper management is crazy if they think the Q4 comp plan is exciting. Very few reps are going to obtain 150 prescriptions in Q3 much less Q4.
     

  2. anonymous

    anonymous Guest

    The question is how many people are going to coast in Q4 while looking for a new job? Only people in the top five have a shot at making the 150 prescriptions to reach the target bonus of $7500.00. Look at your paystub. Did you come close to making the targeted (uncapped bonus) $30k you were told about when you were hired? Does it look more like $20k? The breakdown would be $7500. from Q4 MBOs, $7500. (maybe) from Q1 MBOs which is $15k. While not on MBOs, did you make another $15k grand? Or was it two nickels in Q2 and three quarters in Q3? Everyone needs to take a serious look at their paystubs. Decide whether or not that nice base pay is worth staying for a decrease in bonus every quarter along with increasing crap every quarter. Don't forget that T.N. only wants to pay on new prescriptions in Q1. How are you going to make any money with only new prescriptions?
     
  3. anonymous

    anonymous Guest

    Crappy money for a startup.
     
  4. anonymous

    anonymous Guest

    I could not have said it better. This is a startup and we are still not making money.

    Rayaldee is a good product and will sell. We just need to get out and sell. The money will follow.
     
  5. anonymous

    anonymous Guest

    Well who told the street Rayaldee was going to do $70 million this year when we’ll be lucky to hit $10 million? The same people who are taking salaries and bonuses in the seven figure range. Yet, no money is available to adequately contract, instead relying on 501c3’s to shoulder the burden of tier 3 copays. And on the earnings call the same over compensated individuals lay the blame on the sales force. This is going to get real ugly real soon when the expanded sales force fails to approach the $8-$10 million a quarter needed to break even.
     
  6. anonymous

    anonymous Guest

    There isn't any Foundation money. Scripts will see a downturn and the "bottle count" is going to come to a screeching halt. Patients can't afford the $200. deductible for Vita. D. They need the money for their hypertension and diabetes.

    Coast until you can find something else. I am sick about how little bonus we are making doing this difficult job without reimbursement.
     
  7. anonymous

    anonymous Guest


    Yes.
     
  8. anonymous

    anonymous Guest

    Interesting how the company ran out of samples right after the Foundations ran out of money. Is it bad timing or a devious plan to lower the Q4 bonus potential? How many patients are we going to lose due to no Foundation money, lack of reimbursement and no samples? MB stated on the PAP conference call that the Foundations may not receive an infusion of money until late Jan.
     
  9. anonymous

    anonymous Guest

    No samples too?
     
  10. anonymous

    anonymous Guest

    No samples were sent out last week.
     
  11. anonymous

    anonymous Guest

    Samples are no longer available.